Abliva - KOL Event on KL1333 in Primary Mitochondrial Disease, May 21, 2024

View Abliva's virtual KOL event featuring Amel Karaa, MD (Massachusetts General Hospital), who discusses the unmet medical need and current treatment landscape for patients with primary mitochondrial disease (PMD). There are currently no approved medicines for the systemic disease. The event focuses on Abliva's lead program, KL1333, which has shown clinically meaningful, early signals of efficacy in PMD patients. This novel therapeutic approach modulates the underlying pathophysiology in mitochondrial disease. KL1333 is currently being evaluated in the pivotal Phase 2 FALCON trial, with interim analysis positive readout announced mid-year 2024. KL1333 has Orphan Drug Designation (ODD) in both Europe and the U.S. and Fast Track designation in the U.S.